Presentation is loading. Please wait.

Presentation is loading. Please wait.

Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease  Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,

Published byGarry McDowell Modified over 5 years ago

Similar presentations

Presentation on theme: "Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease  Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,"— Presentation transcript:

1 Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease 
Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD, PhD, Manabu Ono, MD, Tokiwa Tamai, MD, PhD, Masakazu Ichinose, MD, PhD  Journal of Thoracic Oncology  Volume 8, Issue 8, Pages e73-e74 (August 2013) DOI: /JTO.0b013e318293dfc1 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 PET and CT of a 53-year-old woman. Both PET scan (A) and CT scan (B) showed a mass in the right lower lobe with bilateral, multiple pulmonary nodules. PET, positron emission tomography; CT, computed tomography. Journal of Thoracic Oncology 2013 8, e73-e74DOI: ( /JTO.0b013e318293dfc1) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Crizotinib-induced interstitial lung disease. A, A chest CT scan performed 14 days after initiation of crizotinib treatment showing a decrease in size of the main tumor, but visible bilateral ground-glass opacities. B, CT scan 5 days after cessation of crizotinib and initiation of corticosteroid, showed improvement of air space consolidations, despite the right lower lobe tumor enlargement. CT, computed tomography. Journal of Thoracic Oncology 2013 8, e73-e74DOI: ( /JTO.0b013e318293dfc1) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Chest computed tomography scan before and after crizotinib retreatment. A, Before treatment with crizotinib, the scan showed the right lower mass and bilateral lung metastases. B, Two months after the initiation of crizotinib, the scan showed a partial remission of the right lower lung tumor without recurrence of interstitial lung disease. Journal of Thoracic Oncology 2013 8, e73-e74DOI: ( /JTO.0b013e318293dfc1) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease  Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,"

Similar presentations

Neoplastic Fever Caused by Lung Cancer

Neoplastic Fever Caused by Lung Cancer
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Jeffrey Bradley, MD  Journal of Thoracic Oncology 

Jeffrey Bradley, MD  Journal of Thoracic Oncology 
A 51-Year-Old Woman With an Increasing Chest Wall Mass Years After Resection of an Early Stage Lung Cancer  Ajay Dhakal, MBBS, Hongbin Chen, MD, PhD,

A 51-Year-Old Woman With an Increasing Chest Wall Mass Years After Resection of an Early Stage Lung Cancer  Ajay Dhakal, MBBS, Hongbin Chen, MD, PhD,
Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient  Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.

Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient  Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.
Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia  Hiroaki Tachi, MD, Toshihiro Shiozawa, MD, Chio Sakai, MD, Mariko Kasuga,

Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia  Hiroaki Tachi, MD, Toshihiro Shiozawa, MD, Chio Sakai, MD, Mariko Kasuga,
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.
PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Avoidance of completion pneumonectomy by sparing the right middle lobe

Avoidance of completion pneumonectomy by sparing the right middle lobe
Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802)

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH /RO )
Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report  Kazutaka Fujita, MD, Yuko.

Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report  Kazutaka Fujita, MD, Yuko.
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea  Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea  Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1 

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1 
The Moth-Eaten Lung Journal of Thoracic Oncology

The Moth-Eaten Lung Journal of Thoracic Oncology

Similar presentations

Ads by Google